Stereotactic body radiation therapy for locally recurrent, previously irradiated nonsquamous cell cancers of the head and neck.
Publication/Presentation Date
8-1-2012
Abstract
BACKGROUND: Stereotactic body radiotherapy (SBRT) has emerged as a promising salvage strategy for patients with recurrent, previously irradiated head and neck cancer; however, data are limited predominantly to squamous cell carcinomas. Herein, we report the efficacy of SBRT in recurrent, nonsquamous cell cancers of the head and neck (NSCHNs).
METHODS: In all, 34 patients with pathologically proven NSCHN were re-irradiated with SBRT to a median dose of 40 Gy in 5 fractions (interquartile range, 30-44 Gy). Toxicity and quality of life were followed prospectively.
RESULTS: Median follow-up was 10 months (absolute range, 0-55 months). The 6-month/1-year local control rate was 77/59%, with a 6-month/1-year overall survival of 76/59%. Local control was significantly improved for tumors(p = .030). Acute/late grade 3 toxicity was 15/6%, with no grade 4-5 toxicity.
CONCLUSIONS: SBRT for previously irradiated, locally recurrent NSCHN provides promising local control, especially for tumors <25 >mL, with minimal toxicity. The optimal dose for larger tumors remains to be defined.
Volume
34
Issue
8
First Page
1153
Last Page
1161
ISSN
1097-0347
Published In/Presented At
Vargo, J. A., Wegner, R. E., Heron, D. E., Ferris, R. L., Rwigema, J. C., Quinn, A., Gigliotti, P., Ohr, J., Kubicek, G. J., & Burton, S. (2012). Stereotactic body radiation therapy for locally recurrent, previously irradiated nonsquamous cell cancers of the head and neck. Head & neck, 34(8), 1153–1161. https://doi.org/10.1002/hed.21889
Disciplines
Medicine and Health Sciences
PubMedID
22076812
Department(s)
Department of Surgery
Document Type
Article